CereVasc
Summary active Updated Jun 3, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
CereVasc is a Boston-based clinical-stage medical device company developing minimally invasive treatments for neurological diseases 1. Its lead product, the eShunt System, is designed to treat Normal Pressure Hydrocephalus (NPH) by draining excess cerebrospinal fluid from the brain into the venous system through a small implant placed in the cerebellopontine angle, avoiding traditional invasive shunt surgery 1 2.
The Series C proceeds will fund completion of the ongoing STRIDE pivotal trial in NPH patients, operational scale-up, regulatory preparation for a future Premarket Approval (PMA) submission to the FDA, and US commercialization readiness 1.
In conjunction with the financing, the board was strengthened with the addition of Kevin Conroy as lead independent director, Christopher Geyen as independent director and audit committee chair, and Tom Schnettler of Piper Sandler Merchant Banking representing the new Series C investors 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-04 | Series C | $85M | Piper Sandler Merchant Banking | Johnson & Johnson Innovation – JJDC, Medtronic, Bain Capital Life Sciences, Perceptive Xontogeny Venture Funds 1 2 3 |
What Investors Say
No independently sourced investor quotes found at this time.
What Founders Say
No independently sourced founder quotes found at this time.
Sources
-
“CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt System for the Treatment of Normal Pressure Hydrocephalus,” PR Newswire, June 4, 2026. https://www.prnewswire.com/news-releases/cerevasc-inc-announces-over-subscribed-85-million-series-c-financing-to-advance-its-novel-eshunt-system-for-the-treatment-of-normal-pressure-hydrocephalus-302791507.html↩↩↩↩↩
-
“CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing,” BioSpace, June 4, 2026. https://www.biospace.com/press-releases/cerevasc-inc-announces-over-subscribed-85-million-series-c-financing-to-advance-its-novel-eshunt-system-for-the-treatment-of-normal-pressure-hydrocephalus↩↩
-
“Cerevasc announces oversubscribed US$85 million Series C financing round,” NeuroNews International, June 4, 2026. https://neuronewsinternational.com/cerevasc-announces-oversubscribed-us85-million-series-c-financing-round/↩